Eric J. Small, MD, on Prostate Cancer: Results From the SPARTAN Trial

2018 Genitourinary Cancers Symposium

Eric J. Small, MD, of the University of California, San Francisco, discusses phase III findings on apalutamide vs placebo in patients with nonmetastatic castration-resistant prostate cancer (Abstract 161).

Aug

Today In Oncology

FDA Approves Pembrolizumab in Combination With Chemotherapy for First-Line Treatment of Metastatic Nonsquamous NSCLC

FDA Updates Prescribing Information for Pembrolizumab and Atezolizumab in Urothelial Carcinoma

Impact of Doctor-Patient Communication on Outcomes in Cancer Survivors

Cetuximab With Radiotherapy Found to Be Inferior to Standard Treatment in HPV-Positive Oropharyngeal Cancer

Addition of Vincristine and Irinotecan to Vincristine, Dactinomycin, and Cyclophosphamide in Pediatric Intermediate-Risk Rhabdomyosarcoma

;